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Abstract 
 Chimeric Antigen receptor T cell (CAR-T cell) therapy is a novel adoptive 
immunotherapy where T lymphocytes are engineered with synthetic receptors known as 
chimeric antigen receptors (CAR). CARs are engineered and constructed specifically to 
reprogram a patient’s T cells to target tumor cells. These CARs predominantly are used 
to treat hematological malignancies including Lymphoma and Multiple Myeloma. 
Specific targets often used include, CD19, CD20, CD30, and CD138. Although this 
novel therapy is promising it has its disadvantages. CAR T-cell therapy-associated 
toxicities, including cytokine release syndrome, on-target/off-tumor, and other 
neurologic toxicities have been observed and are being properly managed in clinic. In 
this review, the applications of CAR-T cells in different hematological malignancies, the 
anatomy and production of CARs, along with future directions are discussed. This 
technique could pave the way for future improvements on the effectiveness and 
persistence of adoptive immunologic therapies.  
 Introduction 
Adoptive immunotherapy for cancer has a long, and checkered history. William 
Coley is widely attributed with the discovery and the first observation of the immune 
system having antitumor effects. Coley’s observation of the regression of sarcoma 
following severe bacterial infections in the 1890s was the beginnings of adoptive 
immunotherapy (1). However, the pivotal finding that hematopoietic stem cell 
transplantation using syngeneic donors was less effective at preventing relapse of 
leukemia compared with sibling donors provided the backbone for T-cell therapy (2). 
Over the past several years, there has been a spike in potentially beneficial therapies 
stemming from culturing, redirecting, and/or enhancing T-cells against certain tumor cell 
types (3). T-cell based adoptive immunotherapy, which is being developed to deal with 
malignancies, especially hematological cancers. Non-Hodgkin lymphoma and multiple 
myeloma are some of the most commonly treated with these techniques. However, solid 
tumors including, melanoma, breast cancer, and sarcoma have also shown 
susceptibility to adoptive immunotherapy. Three of the emerging therapies for treating 
these malignancies are: tumor infiltrating lymphocytes, T-cell receptor (TCR)-modified 
T-cells, and Chimeric antigen receptor T cells (CAR-T) (4). The first two techniques are 
inefficient due to the process of production, the poor success rate, and the dependence 
upon vaccination which limit development (5). However, CAR-T cell therapy is more 
sustainably efficient and has been over the past two decades. CAR-T cell therapy has 
been viewed with exceptional interest over the past two decades at an array of 
academic institutions. The redirection of the cell-mediated immune response toward 
tumor antigens by expressing chimeric antigen receptors is a hot topic amongst 
researchers.  
 CARS are recombinant receptors that typically target surface molecules (6). CAR 
is typically composed of two separate domains: an extracellular and intracellular 
domain. Typically, the extracellular domain is an antibody single-chain fragment (scFv), 
while the intracellular domain includes fused signaling domains from natural TCR 
complex and costimulatory domains (7). The extracellular domain links via a 
spacer/hinge and transmembrane domains to the intracellular signaling domain that can 
include costimulatory domains and T-cell activation moieties (8). CARs recognize 
unprocessed antigens independently of their expression of major histocompatibility 
antigens, which is different from the physiologic T-cell receptors (TCRs). Hence, CAR T-
cells are able to circumvent some of the major mechanisms by which tumors avoid 
MHC-restricted T-cell recognition (8). Another feature of CARs is their ability to bind to 
not only proteins but to carbohydrates (9), gangliosides (10), proteoglycan (11), and 
heavily glycosylated proteins (12) thereby expanding potential targets for binding. CARs 
engage the target via the single-chain variable fragment (scfv) derived from antibodies, 
although natural ligands have been used as well. However, the scfvs derived from 
murine immunoglobulins are the most common.  
 Of crucial importance for CAR design is the intracellular signaling modules, which 
are derived from lymphocyte signal-initiating molecules. These are known as first-
generation CAR design that include specific chains of the TCR/CD3 complex and the 
high-affinity receptor for immunoglobulin E. These were shown to activate cellular 
responses to diseased cells (13). Tumor cells are able to induce specific tolerances of 
antigens based on MHC class I-restricted antigen presentation and a simultaneous lack 
of costimulatory ligands. The design and anatomy behind CAR attempts to provide the 
appropriate signals to activate effector T-cells. Each incorporation of simultaneous 
costimulatory signals improves the response and activation of the effector T-cells to 
handle the affected tissue. The adding of costimulatory signals is known as second-
generation CAR. Lacking the signals creates a first-generation CAR. Altering the 
signaling molecules that are attached to CD3 define the structures. Those that posses 
CD3 along with signaling endo-domains, such as, CD28, CD134, OX40 (CD134), or 
CD137 (4-1BB) are known as second and third generation CARs (Fig. 1). These 
structures imitate the costimulation signal when TCR combines with antigen presenting 
cells to complete the process of activation.
 
Figure 1 
Illustration of basic structure of 4 generations of chimeric antigen receptor T cells (CAR-T cell) 
and common targets on tumor cells. The whole structure of CARs consisted of an antibody 
single-chain fragment (scFv, extracellular segment) specifically against a cell surface antigen as 
well as one or several fused signaling domain(s) from natural TCR complex and costimulatory 
molecules (intracellular segment). Different intracellular segments represent various CAR-T cell 
generations. scFv, single-chain fragment. TM, transmembrane region. 
 
All of these generate CAR-T cell specificity for a certain type of cancer which leads to 
their elimination. Because of the monoclonal antibody against tumor antigen offers 
novel T cell specificity for certain types of cancer cells and bypasses the established 
antigen-presenting process, an important strength of this method is that the recognition 
is independent of the MHC (7). Nevertheless, a novel generation of CARs has proven 
attractive to scientists. However, recently, studies have been performed on optimizing 
CAR design. Fourth generation CAR T-cells contain a cytokine killing mechanism, they 
are known as TRUCKs or T-cell redirected for universal cytokine killing. The cytokine, 
usually pro-inflammatory cytokine, may be constitutively produced or induced once the 
T cell is activated. The mechanism is to deposit inflammatory cytokines in the targeted 
tumor site, which attracts an innate immune response toward those cancers cells that 
are invisible to CAR T-cells (14). These properties have demonstrated the ability to 
decrease tumor growth and development within hematological carcinomas and are 
likely to translate to immunotherapy of solid tumors.  
In general, the process of manufacturing and delivery of CAR-T involves the 
following and is complicated. (fig 2). Firstly, T cells from peripheral blood are collected 
by leukapheresis, followed by apheresis without adding colony stimulating factor. 
Colony stimulating factor can cause disruption in the proliferation of the T cells, along 
with their responsiveness (15). Antibody coated beads serving as artificial dendritic cells 
are used to activate the isolated T cells. The genetically reprogrammed T cells are then 
transfected ex vivo with a CAR viral or non-viral vector, where a section of genome DNA 
is inserted. T-cell ex vivo expansion and purification are the subsequent and key steps, 
determining the efficacy of this novel adoptive immunotherapy (15). Finally, test of cell 
quality and sterility are needed, which take around 2-4 weeks to complete (16). Before 
T-cell infusion, the patient receives a preparative lymphodepleting regimen and then the 
CAR T-cell infusion occurs.  
 
Figure 2 
Flow chart of the whole procedure of the chimeric antigen receptor T cell (CAR-T cell) 
production 
 
Patients with disease deterioration after primary and secondary therapies for 
lymphoma have been found to have poor prognosis even after improvements through 
cytotoxic chemotherapy regimens and monoclonal antibody therapies (17).  However, 
CAR-T cell therapies are among the latest advanced immunotherapies for relapse or 
chemotherapy-refractory B-cell non-Hodgkin lymphoma (18).  
There are several types of CARs modified on the surface of T cells. The anti-
CD19 CAR-T cell is the earliest and the most traditional, however, CD20 and CD30 are 
potential targets along with many others for multiple B cell malignancies. For lymphoma, 
the first generation of CAR-T cells were not effective in preventing proliferation, 
persistence and homing compared to the second and third generations (17). Two 
different studies have reported preclinical results showing superior proliferative and 
antitumor activities of the second and third generation T cells, with the CD28 or 4-1BB 
cytoplasmic signaling domains, both in vitro and in vivo (19). Despite a positive effect of 
CD28 as an early signal in improving cell expansion and persistence, some trials have 
suggested that using CAR containing 4-1BB as a late costimulatory signal yields more 
remarkable expansion and anti-tumor activity in indolent B cell malignancies (20). For 
example, CTL019 therapy has shown great effect in some patients with advanced 
relapse/refractory (r/r) follicular lymphoma (FL) and diffuse large B-cell lymphoma 
(DLBCL). Among 8 eligible patients, 4 people had responses at different levels: 3 
complete remissions (CR rate is 13%) and 1 partial remission (PR rate is 4%), with a 
50% 3-month overall response rate. Four patients with DLBCL had progressive disease 
before or at initial response assessment, and there was no treatment-related mortality 
(21). 
Besides CD19 other surface markers are also essential. CD20, a trans-
membrane protein presents in more than 90% of B-cell lymphomas, as well as being a 
well-established target for non-Hodgkin Lymphoma treatments (22). Currently, first–
generation anti-CD20 CAR-T cell therapy has been used in several studies. In one 
clinical trial study 7 participants suffering from lymphomas were treated. Two patients in 
this study achieved CR, 1 subject got a PR while the disease in another 4 patients was 
stable (23). To test whether the second-generation of CAR-T treatment is effective in 
DLBCL patients, a study in 2014 using anti-CD20 CAR-T cell with 4-1BB reported a 
promising effect of this novel treatment (22). To test whether the second-generation of 
CAR-T treatment is effective in DLBCL patients, a study in 2014 using anti-CD20 CAR-
T cell with 4-1BB reported a promising effect of this novel treatment (22). In this study, 7 
patients with refractory advanced CD20+ DLBCL were recruited. Among them, 5 
patients were hampered with bulky tumors and the other 2 were not. Except for 1 
subject, the other 6 patients received preconditioning chemotherapy for disease control 
or the tumor was debulked before anti-CD20 CAR-T cell infusion. One of the two 
patients without a bulky tumor burden achieved a 14-month long lasting and ongoing 
CR without preconditioning regimen, and another gained a 6-month tumor regression. 3 
of 5 with bulky tumors got 3- to 6-month tumor regression (22).  
Multiple Myeloma (MM) is a bone marrow derived malignancy leading to anemia, 
immunosuppression, hypercalcemia, and renal insufficiency (24). Despite multiple 
techniques to slow and eradicate, this disease remains incurable. However, the fact that 
myeloma can subside as a result of the graft-versus-myeloma effect in allogeneic stem 
cell transplantation provides insight into the role of T-cell-based immunotherapy (25). 
These techniques use many biomarkers to eliminate the malignancies from circulation. 
One of the most popular, as mentioned above is CD19. However, CD19 is minimally 
expressed on the surface. This lower expression does not allow the anti-CD19 CAR-T 
cells in bind and perform well to kill the malignant cells (26). It is evident then that more 
specific targets should be explored to treat MM. CD138 and B-cell maturation antigen 
(BCMA, CD269) have been identified as molecules that show promising 
immunotherapeutic potential in treatment of MM. By virtue of its expression in nearly all 
MM patients, CD138 is used as a primary diagnostic marker (27). The result of a clinical 
trial using second-generation of anti-CD138 CAR-T cell treatment of 5 refractory MM 
subjects showed that, after 7-month follow-up treatment, the conditions of at least 4 
patients were stable and one patient with advanced plasma cell leukemia had a 
reduction of myeloma cells in peripheral blood (28). The results of this clinical trial show 
CAR-T cell therapy for MM is tolerable and has anti-tumor immunity when using anti-
CD138. BCMA also has potential in treatment of MM. This technique uses anti-BCMA to 
cripple the survival of long-lived plasma cells within MM patients. In a clinical trial, 
patients were administered BCMA/CD269 CAR-T cells in a dose-escalation. 6 patients 
were treated at the lowest 2 dose levels, low anti-myeloma activity or toxicity was 
noticed. Additionally, at the third dose level 1 patient obtained partial remission. 
Furthermore, two chemotherapy-resistant patients were treated on the fourth dose level 
with anti-BCMA CAR-T and achieved complete remission lasting for 17 weeks before 
relapse (29). Similar ongoing studies have shown therapeutic outcomes as well. Many 
new approaches to treat MM have progressed and been achieved in vitro. Hopefully, 
many more trials will usher in a new era of MM immunotherapy.  
CAR-T cell as an immunotherapeutic effect has its advantages and 
disadvantages. In contrast with common adaptive immune cells, CAR-T cells have 
unique specificity and can eliminate cancer cells containing the unique and 
corresponding antigen. To some extent this technique will avoid killing healthy tissues. 
Furthermore, CAR-T cells have MHC-unrestricted activity, they can circumvent some 
major mechanisms by which tumors avoid MHC-restricted T cell recognition. For 
example, the down regulation of human leukocyte antigen class I molecules (30). In 
addition, the flexibility of the intracellular signaling domains permits the cell to 
counteract the down-regulation of co-stimulatory molecules. Also, the potential that 
CAR-T cells can bind to multiple different antigen forms such as, carbohydrates, lipids, 
and proteins leads to many different potential combinations (31).  
When treating hematological malignancies using CAR-T cells there are many 
advantages and promising results, however, there are some disadvantages as well. 
Neurologic toxicity is a serious potential toxicity from CAR-T cell therapy and it has been 
observed in some clinical trials. Some symptoms include, delirium, dysphasia, akinetic 
mutism, and seizures have been reported (32). Endothelial dysfunction, including 
vascular instability, capillary leak, blood-brain barrier disruption and disseminated 
intravascular coagulation are clinical evidence of neurotoxicity (33). Some of the prime 
molecules that have been identified as inducing acute neurotoxicity are, IL6, IFN-γ and 
TNF.  
Similarly, another disadvantage of CAR-T cell therapy is cytokine release 
syndrome which is caused by release of the same proinflammatory cytokines mentioned 
above. Cytokine release syndrome (CRS) which manifests in high fevers, hypotension, 
and hypoxia potential organ failure is related to the release and production of IL6, IFN-γ 
and TNF, secondary to the production of CAR T-cell activation (34). Systemic 
corticosteroids are used to treat the hyper-proliferative effects of CRS. However, the 
downside is the rapid ablation of these T cells with decrease the efficacy of CD19 CAR-
T cells, which could trigger a relapse (35). Thus, a new way of treatment has to be 
found. Tocilizumab, an anti-IL-6 receptor antagonist is being used to weaken the effects 
of CRS.  
The last major concern for CAR T-cell is known as on-target/off-toxicity. Although 
CAR T-cells have relative specificity it has been observed that these cells can still affect 
different levels of tissue and cause damage, especially in the lymphatic tissues. This 
includes B cell aplasia in anti-CD19/CD20 CAR-T cell treatment. Also, antigen escape, 
typically CD19-negative relapse of B cell malignancy, may challenge the success rate of 
CARs in blood cancer (36).  
To broaden the application of the T-cell therapy, is desirable to develop 
techniques that increase the efficiency and promote safety at each step in the process. 
CAR T-cell therapy is an emerging and powerful therapy that is likely to be incorporated 
into the mainstream oncologic treatment. Although challenges remain in the 
manufacturing of the single-patient products, in which the raw materials are derived 
from the patient’s own cells, technologies for isolating, culturing, and improving the 
efficacy are rapidly increasing. In the longer term the development of universal T-cell 
products from allogenic donors is in the works. However, it remains to be seen whether 
universal T-cell products are as potent and durable as those collected from the patients 
own blood stream.  
In addition to manufacturing improvements, research is ongoing to identify, 
validate, and target lineage-specific antigens or tumor-associated antigens in other 
cancers. Theoretically, CAR T cells can result in deleterious effects by damaging 
healthy organs and structures when tumor-associated antigens are expressed on 
normal cells. Thus, the potential on-target but off-tumor effects must be investigated for 
each candidate antigen. Additionally, the benefit of therapy versus this potential cost 
must be considered for each disease before considering CAR technology. Preclinical 
models are currently investigating CARs coexpressed with other genes to improve 
various characteristics of the modified T cell, such as safety, persistence, and effector 
functions. For example, current research involving engineering CAR T cells to also 
express the NKG2D receptor coupled to CD3-zeta (37). This receptor engages several 
stress ligands that are known to be upregulated on tumor cells, and evidence suggests 
that the genetically reprogrammed T cells also target inhibitory regulatory T cells (Tregs) 
for destruction. Additionally, CAR T cells can be further modified with additional 
transgenes that can express specific cytokines to promote the recruitment of tumor-
associated macrophages, thereby enhancing both the antigen-presenting and tumor 
lytic activity of T cells (38). To date, this is only one of many different directions that 
CAR T-cell therapy can move in. However, many other inquiries still need to be made 
into the negative side effects of use.  
Furthermore, research testing the preclinical function and safety of these 
techniques has largely been explored in murine models. While preclinical human 
xenograft mouse models in immune compromised mice played an important role in 
establishing proof-of-principle of the CAR T cell approach, they are limited in their 
clinical relevance and predictive value. Specifically, injected tumors in immune 
compromised mice may not fully recapitulate the immunosuppressive tumor 
microenvironment. Given the rapid and ongoing advances in CAR T cell technology in 
the laboratory, it now becomes necessary to identify and develop methodologies that 
will allow us to evaluate CAR T cell therapy in dogs with spontaneous cancers. This 
approach will enable us to determine and optimize the safety of novel targets and the 
therapeutic effectiveness of redirected T cells. This would accelerate the translation of 
the safest and most promising CAR therapies into the human clinic. 
Pet dogs share a very close relationship and living environment with humans and 
develop cancers with similar biology and outcomes (39). Additionally, companion dogs 
with spontaneous cancers are being increasingly recognized as a relevant and 
potentially predictive preclinical model of human disease and could be effectively used 
to test the safety and efficacy of next generation CAR T cell therapies (40). In particular, 
canine cancer patients lend themselves far better than murine models for the evaluation 
of immunotherapies, including assessment of preconditioning regimes, engraftment, 
cellular trafficking into malignant lesions, transferred cell persistence, immune memory 
development, and effectiveness in preventing relapse (41).  
The field of cancer immunotherapy has rapidly developed over the past decade. 
Such genetic modifications allow us to evolve an expanding field. These therapies have 
shown promise for the future of treating and potentially curing patients with advanced 
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